Nano vaccines for T. gondii Ribosomal P2 Protein With Nanomaterials as a Promising DNA Vaccine Against Toxoplasmosis

• DOI: 10.3389/fimmu.2022.839489
• Publication Date: 2022-02-21T11:04:17Z
• Authors: ZhengQing Yu; Ke He; WanDi Cao; Muhammad Tahir Aleem; RuoFeng Yan; LiXin Xu; XiaoKai Song; XiangRui Li
• Keywords: PLGA; Toxoplasmosis

Caused by Toxoplasma gondii , toxoplasmosis has aroused great threats to public health around the world. So far, no effective vaccine or drug is commercially available, and demands for a safe therapeutic strategy have become more urgent. In current study, we constructed DNA encoding T. ribosomal P2 protein (TgP2) denoted as TgP2-pVAX1 plasmid. To improve immunoprotection, nanomaterial poly-lactic- co -glycolic acid (PLGA) chitosan were used delivery vehicle construct TgP2-pVAX1/PLGA TgP2-pVAX1/CS nanospheres. Before vaccinations in BALB/c mice, plasmids transiently transfected into Human Embryonic Kidney (HEK) 293-T cells, expression of eukaryotic was detected laser confocal microscopy Western blotting. Then immunoprotection naked their two nano-encapsulations evaluated laboratory animal model. According investigations antibody, cytokine, dendritic cell (DC) maturation, molecule expression, splenocyte proliferation, T lymphocyte proportion, plasmid delivered types nanospheres could elicit mixed Th1/Th2 immune response Th1 immunity dominant. addition, advantages enhancing against lethal dose RH strain challenge. All these results suggested that PLGA be promising vaccines resisting deserve further applications.